Infections and cancer: Established associations and new hypotheses
Introduction
Around the world, infection is one of the most important causes of cancer [1]. It was estimated conservatively that in the year 2002, 18% of all malignancies were attributable to infectious agents [2]. Among infection-related neoplasms, cancers of the stomach, liver and cervix uteri detain the highest incidence figures, and are known to be largely attributable to Helicobacter pylori, hepatitis B and C viruses, and human papilloma virus, respectively. In terms of overall mortality, cancers of the stomach in men, and cervix uteri in women, rank second and third worldwide, while liver cancer ranks third and sixth for men and women, respectively [3].
Section snippets
H. pylori: the bacterium
H. pylori is a spiral shaped Gram negative bacterium that is transmitted from human to human, usually during early childhood, and colonizes the gastric epithelium for a lifetime in the absence of specific antimicrobial therapy. In industrialized countries, the improvement of sanitation and hygiene has been responsible for a dramatic decrease in transmission during the last few decades, and the epidemiology of the bacterium now typically follows a birth cohort model: older people (infected
Epstein-Barr virus (EBV)
EBV is a DNA virus of the herpes virus family that establishes a latent infection and life-long persistence in more than 90% of the population in the world. The virus is transmitted by saliva and initially infects the epithelium of the oropharynx, from which it spreads into B-cells of the lymphoid tissue [74]. Most primary EBV infections are subclinical. In developing countries 80% children are infected by the age of 3. In developed countries, primary infection is usually delayed until
Conclusion and new hypotheses
In epidemiology, a common definition of the attributable fraction is the proportion of disease occurrence that would potentially be eliminated if a specific exposure were prevented. Calculations based on relative risks from well conducted epidemiological studies and population prevalence data have led to the estimate that there would be 17.8% fewer cancers worldwide (26.3% in developing countries and 7.7% in developed countries) if chronic infections with known carcinogenic infectious agents
Conflict of interest
Catherine de Martel and Silvia Franceschi have no conflict of interest to declare.
Reviewers
Dr. Carlo La Vecchia, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62, I-20157 Milan, Italy.
Dr. Luigino Dal Maso, Centro di Riferimento Oncologico, Serv. Epidemiologia, Via Franco Gallini, 2, Aviano, PN, Italy.
Prof. Fabio Levi, IUMSP, CHUV, Cancer Epidemiology Unit, Rue du Bugnon 17, CH-1005 Lausanne, Switzerland.
Acknowledgment
The authors would like to thank S. Nouveau for editorial assistance.
Dr. Catherine de Martel received her medical degree from the Bichat-Claude Bernard University in Paris, France. After her residency, she joined the French National Agency for Research on AIDS (ANRS) as a research assistant for a few years. She then received a M.S. and a Ph.D. in infectious disease epidemiology from Stanford University School of Medicine, Stanford, California, and worked on Helicobacter pylori associated cancers in the department of Medicine. She now collaborates with the
References (118)
- et al.
Carcinogenesis of Helicobacter pylori
Gastroenterology
(2007) - et al.
Helicobacter pylori vaccine: from past to future
Mayo Clin Proc
(2008) - et al.
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Blood
(2006) - et al.
Chapter 2: the burden of HPV-related cancers
Vaccine
(2006) - et al.
Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis
Lancet
(2005) - et al.
The current and future role of screening in the era of HPV vaccination
Gynecol Oncol
(2008) - et al.
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Lancet
(2007) - et al.
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Lancet
(2006) - et al.
Mouse models for the study of HCV infection and virus–host interactions
J Hepatol
(2008) - et al.
Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies
Gastroenterology
(2007)
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation
Cell
Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions
Cancer Lett
Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Lancet Infect Dis
Cancer and infection: estimates of the attributable fraction in 1990
Cancer Epidemiol Biomarkers Prev
The global health burden of infection-associated cancers in the year 2002
Int J Cancer
GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, IARC CancerBase No. 5, version 2.0
IARC monographs on the evaluation of carcinogenic risks to humans
Schistosomes liver flukes and Helicobacter pylori, vol. 61
Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma
J Infect Dis
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts
Gut
Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma
J Infect Dis
Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions
J Natl Cancer Inst
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma
J Natl Cancer Inst
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
Nature
A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study
Int J Cancer
Gastric cancer originating from bone marrow-derived cells
Science
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial
JAMA
Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial
Cancer Epidemiol Biomarkers Prev
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication
Gut
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy
J Natl Cancer Inst
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions
J Natl Cancer Inst
Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population
J Natl Cancer Inst
A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States
Emerg Infect Dis
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas
J Natl Cancer Inst
Immunoproliferative small intestinal disease associated with Campylobacter jejuni
N Engl J Med
Helicobacter pylori infection and gastric lymphoma
N Engl J Med
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma
J Natl Cancer Inst
IARC monographs on the evaluation of carcinogenic risks to humans
Human papilloma viruses, vol. 90
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update
Int J Cancer
Risk of female human papillomavirus acquisition associated with first male sex partner
J Infect Dis
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
J Infect Dis
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys
Int J Epidemiol
Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya
Int J Cancer
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys
Cancer Epidemiol Biomarkers Prev
Human papillomavirus types among women infected with HIV: a meta-analysis
AIDS
Circumcision and human papillomavirus infection in men: a site-specific comparison
J Infect Dis
IARC monographs on the evaluation of carcinogenic risks to humans
Human papillomaviruses, vol. 64
Association of human papillomavirus types 16 and 18 E6 proteins with p53
Science
Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality
J Natl Cancer Inst Monogr
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case–control study
Int J Cancer
Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies
Int J Cancer
Cited by (205)
Medical Jeopardy Quiz: Infections and Cancer
2023, American Journal of MedicineArsenic-induced mutagenesis and carcinogenesis: A possible mechanism
2023, Handbook of Arsenic ToxicologyHigh prevalence of Cryptosporidium infection in Iranian patients suffering from colorectal cancer
2022, Parasite Epidemiology and ControlGut microbes in gastrointestinal cancers
2022, Seminars in Cancer BiologyAssociation of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study
2022, Revista de Gastroenterologia de MexicoProstate diseases and microbiome in the prostate, gut, and urine
2022, Prostate International
Dr. Catherine de Martel received her medical degree from the Bichat-Claude Bernard University in Paris, France. After her residency, she joined the French National Agency for Research on AIDS (ANRS) as a research assistant for a few years. She then received a M.S. and a Ph.D. in infectious disease epidemiology from Stanford University School of Medicine, Stanford, California, and worked on Helicobacter pylori associated cancers in the department of Medicine. She now collaborates with the International Agency of Research on Cancer (IARC) on research projects involving infection-associated cancers.
Dr. Silvia Franceschi received her medical degree from the University of Milan, Italy, where she was trained as a gynecologist. Since medical school, she has been interested in epidemiology and statistics, and obtained a post-graduate diploma in medical statistics from the University of Pavia and a M.S. from the Division of Epidemiology of the Imperial Cancer Research Fund, Oxford, UK. After having directed the Epidemiology Unit of the Aviano Cancer Center from 1984 to 2000, Dr. Silvia Franceschi became, in 2000, Head of the Infections and Cancer Epidemiology Group and, in 2004, coordinator of the Epidemiology and Biology Cluster at the International Agency for Research on Cancer (IARC), Lyon, France. In the context of IARC, she has chiefly been involved in studies on infectious diseases and cancer, most notably human papilloma virus and cervical and oral cancer, HIV and hepatitis C virus and lymphomas, and Helicobacter pylori and stomach cancer. All her studies involve broad international collaborations, mainly with Latin-America, Asia and Africa. Over the years she has closely collaborated with several research centers in the United States (National Cancer Institute) and Oxford, especially in respect to meta-analyses and pooled analyses (e.g., cancers of the breast, thyroid, and cervix).